Genetic polymorphisms of IL-28B are associated with sustained virologic response in patients with chronic hepatitis C / 中华肝脏病杂志

ABSTRACT

<p><b>OBJECTIVE</b>To explore the relationship between polymorphism in the interleukin (IL)-28B gene and sustained virologic response (SVR) in chronic hepatitis C (CHC) patients.</p><p><b>METHODS</b>A total of 220 patients with CHC were prospectively treated with pegylated-interferon (peg-IFN) in combination with ribavirin (RBV) for 48 weeks, and followed-up for an additional 24 weeks. All patients were genotyped for the rs8099917 polymorphism and correlations with antiviral efficacy were determined by statistical analysis.</p><p><b>RESULTS</b>One-hundred-and-eighty-two (82.7%) of the patients achieved end-of-treatment virological response (ETVR). Significantly more patients in the ETVR group carried the rs8099917 genotypes of TT (93.5%) and GT+GG (68.8%), compared to the patients who did not achieve ETVR (X2=23.287, P less than 0.01). In addition, the patients who achieved SVR also represented significantly higher rates of both genotypes (TT 86.2% and GT+GG 60.6%; X2=15.531, P less than 0.01). In the SVR group TT vs. GT+GG odds ratio (OR)=4.063, 95% confidence interval (CI) 1.972-8.369; X2=15.531, P less than 0.01. In the RP group TT vs. GT+GG OR=0.246, 95% CI 0.119-0.507; X2=15.531, P less than 0.01).</p><p><b>CONCLUSION</b>The IL-28B rs8099917 genotype is closely related to antiviral response of patients with chronic hepatitis C. Compared to carriers of the GT and GG genotypes, carriers of the TT genotype have higher SVR rates and lower RP rates. The TT genotype may be an important predictor of antiviral efficacy.</p>